PNC Financial Services Group
AARD

PNC Financial Services Group’s Aardvark Therapeutics AARD Stock Holding History

PNC Financial Services Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106 Buy
+28
New +$290 ﹤0.01% 5093
2025
Q4 		– Sell
-140
Closed -$1.86K – 5342
2025
Q3 		$1.86K Buy
+140
New +$1.58K ﹤0.01% 4518

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PNC Financial Services Group's AARD Position: Q1 2026 in Review

PNC Financial Services Group opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 28 shares worth $106. The stake represents ﹤0.01% of the portfolio and ranks #5093 among its holdings. This is a return to the name: PNC Financial Services Group previously reported a position in AARD as recently as Q3 2025.

PNC Financial Services Group first reported a position in AARD in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.86K in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • PNC Financial Services Group held 28 shares of Aardvark Therapeutics worth $106 as of Q1 2026.
  • Aardvark Therapeutics was a new PNC Financial Services Group position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5093 holding.
  • PNC Financial Services Group first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • PNC Financial Services Group's Aardvark Therapeutics position peaked at $1.86K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.